Transforming precision medicine through AI-powered computational biology
Neovivum is a deep-tech biotechnology company developing AI-powered computational platforms that model, simulate, and predict the behaviour of complex biological systems.
Precision Medicine
Cancer digital twinsPatient-specific predictionAI-assisted therapy modelling
Computational Biology
Biological modellingKnowledge graphsMulti-modal AIEvolutionary algorithms
Digital Agents & Adaptive AI
Metacognitive AIMulti-agent systems
Designation for the CancerScan Digital Twin System, 2026
CancerScan and ABIGAIL4D, funded by the European Innovation Council
Medical device manufacturer, SRN RS-MF-000059103
Built on Horizon 2020 and Horizon Europe projects
Built for real clinics, not benchmark datasets.
Research AI often fails in hospitals: it needs huge datasets, hides its reasoning, and breaks on new patient populations. Our systems were designed from first principles for limited data, regulatory scrutiny, and clinician trust.
Context-aware intelligence
Spatial, temporal, and microenvironmental context, because the same mutation means different things in different tumours.
Minimal-data learning
One-shot and few-shot learning for rare subtypes and small cohorts, augmented by knowledge graphs.
Continuous self-improvement
Runtime ontology updating lets twins refine their knowledge as new evidence arrives, without full retraining.
Explainable by design
Auditable biological reasoning chains and uncertainty estimates that regulators and clinicians can follow.
Multi-modal integration
Imaging, omics, organoids, and clinical outcomes inform one model, across hospitals and lab equipment.
From research platform to clinical decision support.
EIC PathfinderEMA Breakthrough DeviceNeovivum-led
Smart pathology slide scanner for diagnosis and patient-specific treatment recommendation in oncology.
Tumour digital twins that model the tumour microenvironment to predict therapy response and resistance, starting with pancreatic cancer, where no validated individualised treatment-selection tool exists.
EIC PathfinderStarted October 2026
Advancing Breast cancer Individualised Generative AI for Longitudinal Outcomes.
A 4D generative AI system that learns how early breast cancer evolves over time, estimating the benefit and risk of each treatment strategy while keeping clinicians fully in control.
Also in development: GLIOTWIN, CROWNED, MOSAIC, MINDSET, and SOFTWIN, research concepts under review for future funding. All projects
Collaborative modelling & simulation
For biotech and pharma companies, medical device developers, and research groups whose biological systems are too complex, costly, or slow to explore by experiment alone, without building an in-house modelling team.
Available as fee-for-service work or as the modelling partner in a funded grant consortium.
Feasibility study
Establish whether a modelling approach is viable before larger investment.
Full simulation campaign
From setup through parametric exploration to validated prediction: tumour progression, drug transport, coupled multiphysics.
Methodology development
Where the capability you need does not exist yet, we develop the method itself.
Nine years of European research behind every model.
Neovivum builds on the work of CEO Igor Balaž and his team at the University of Novi Sad, together with a network of academic, clinical, and industrial partners across Europe.
Evolvable platform for programmable nanoparticle-based cancer therapies
Rapid development of personalised nanomedicine drug delivery
Modular framework for designing and producing biohybrid machines
ONR Global grant for evolvable digital metacognitive agents
CancerScan designated; ABIGAIL4D begins